Switzerland: Anjarium Biosciences appoints Yoo to CEO position

Anjarium Biosciences, a biotech company focused on creating and delivering a new class of non-viral gene therapies, has appointed Stephen Yoo as CEO. Yoo brings experience in building early-stage life sciences companies, having worked in the industry for 14 years. He was most recently chief medical officer (CMO) and head of R&D at Third Harmonic Bio…

You must be a HMI Subscriber to view this content.

Subscribe Now »